

APPENDIX A

VERSION WITH MARKINGS TO SHOW CHANGES MADE

52. (Three times amended) A method of detecting a lysosomal storage disorder (LSD), monitoring the progress of a LSD or the efficacy of treatment of a LSD in a human or animal subject, the method comprising assaying the level of a LSD marker in a biological sample derived from the subject, wherein the LSD marker is selected from the group consisting of Lamp-1 (lysosome-associated membrane protein type-1), 4-sulphatase, ~~acid phosphatase (ACP), and β -hexosaminidase, and α -mannosidase~~, and β -hexosaminidase, an increase in the level of the LSD marker in the subject relative to the corresponding level of the LSD marker in a non-affected individual or population being indicative of a LSD.

55. (Twice amended) The method according to claim ~~53~~52, wherein the LSD marker is Lamp-1.

59. (Once amended) The method according to claim ~~54~~55, wherein the biological sample comprises blood, plasma, urine, a fibroblast cell, a fibroblast cell culture or a fibroblast cellular extract.

68. (Twice amended) The method according to claim ~~67~~66, wherein the one or more antibodies are monoclonal antibodies.